Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and...

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Methionine adenosyltransferase 2A (MAT2A) is a key enzyme in S-adenosyl methionine (SAM) production.
• MAT2A inhibition is a synthetic lethal strategy for cancers lacking methylthioadenosine phosphorylase (MTAP).
• Targeting MAT2A offers a promising therapeutic approach for specific cancer types.

Purpose of the Study:

• To identify novel MAT2A inhibitors with improved in vivo properties.
• To develop brain-penetrant MAT2A inhibitors for potential CNS applications.
• To advance the therapeutic utility of MAT2A inhibitors in oncology.

Main Methods:

• High-throughput screening was employed to identify initial hits.
• Structure-based design principles, derived from the first-in-class inhibitor AG-270, were utilized for optimization.
• Lead compounds were characterized for their in vivo properties, including brain penetration.

Main Results:

• Two novel lead compounds, AGI-41998 and AGI-43192, were identified.
• AGI-41998 exhibits brain-penetrant properties, while AGI-43192 is potent but has limited brain penetration.
• These compounds demonstrate distinct in vivo profiles, enhancing their potential therapeutic applications.

Conclusions:

• Novel MAT2A inhibitors with distinct in vivo characteristics have been discovered.
• The development of brain-penetrant MAT2A inhibitors opens new therapeutic possibilities for CNS-related diseases.
• These findings support further exploration of SAM modulation in cancer and neurological disorders.